Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CV Regular (also known as CV Regular Drop) is a medical cannabis flower product distributed by the German pharmaceutical company DEMECAN and cultivated by the Canadian producer Cielo Verde. It is an unirradiated, high-THC medical cannabis flower (typically containing approximately 25% THC and less than 1% CBD) available in various cultivars/strains, such as Moby Dick (a Sativa-dominant hybrid), Banana Daddy, Banana Kush, and Shake Back. The product is prescribed for the treatment of various conditions, including chronic pain, depression, ADHD, exhaustion, sleep disorders, and anxiety. Its therapeutic effects are primarily mediated by tetrahydrocannabinol (THC) acting as a partial agonist on cannabinoid receptors CB1 and CB2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CV Regular.